Spots Global Cancer Trial Database for N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors
Official Title: N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors
Study ID: NCT01913093
Conditions
Interventions
Study Description
Brief Summary: To find possible therapeutic targets to help prevent long-term brain and behavioural side effects in survivors of childhood leukemia that may have been caused by chemotherapy (Treatment-Related late Adverse Neuro-Cognitive Effects: TRANCE). The study hypothesis is that genetic variations of the elements in the folate-related cycles and methotrexate disposition networks are associated with the deficit phenotype (TRANCE) of childhood leukemia survivors.
Detailed Description: Hypothesis Genetic variants of the elements in the folate-related cycles and methotrexate disposition networks are associated with the TRANCE phenotype of childhood leukemia survivors. Objectives 1. To identify TRANCE phenotypes of the childhood leukemia survivors. 2. To characterize the folate and vitamin B12 levels of these children 3. To identify DNA methylation patterns associated with TRANCE trait in the leukemia survivors 4. To identify SNPs associated with the TRANCE trait in the leukemia survivors. 5. To identify the "deficit genotype" associated only with the TRANCE leukemia survivors, but not with general population children who show developmental phenotypes similar to TRANCE: TRANCE-unique deficit variant 6. To replicate the association between the TRANCE-unique deficit variants and the TRANCE trait in a population of childhood leukemia survivors. 7. To evaluate the importance of rare genetic variants in the TRANCE trait in the leukemia survivors. Study design: A case-control study of leukemia survivors Analyses 1. Leukemia survivors will be characterized by their status of neurocognitive function, and categorized into the Deficit case and the non-deficit Control case. 2. They will be also characterized by the following attributes 1. Pathway-based genetic variant status (folate and PK-related genes) 2. Folate and vitamin B12 status 3. Epigenetic markers 3. Comparative analyses between neuro-cognitiive deficit phenotype (TRANCE) and Control on those parameters
Eligibility
Minimum Age: 8 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Hospital for Sick Children, Toronto, Ontario, Canada
Contact Details
Name: Dr. Shinya Ito, MD
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Name: Dr. Sharon Guger
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Name: Dr. Johann Hitzler
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Name: Dr. Deborah L O'Connor
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Name: Dr. Russell Schachar
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Name: Dr. Brenda Spiegler
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Name: Dr. Rosanna Weksberg
Affiliation: The Hospital for Sick Children
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
